Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas

April 4th 2022

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Relacorilant/Nab-Paclitaxel Combo Improves OS in Recurrent, Platinum-Resistant Ovarian Cancer

March 31st 2022

The addition of relacorilant to nab-paclitaxel improved overall survival compared with nab-paclitaxel alone in patients with recurrent, platinum-resistant ovarian cancer.

Frontline Maintenance Rucaparib Significantly Improves PFS in Ovarian Cancer Irrespective of Biomarker Status

March 31st 2022

Rucaparib significantly improved investigator-assessed progression-free survival over placebo when used as maintenance treatment in newly diagnosed patients with advanced ovarian cancer following successful first-line treatment with platinum-based chemotherapy, according to top-line findings from the monotherapy arm of the phase 3 ATHENA trial.

Management of Adverse Events After Combination Lenvatinib/Pembrolizumab

March 29th 2022

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Treatment Modification Rates for Combination Lenvatinib/Pembrolizumab

March 29th 2022

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

Pembrolizumab Plus Chemo With or Without Bevacizumab Approaches EU Approval for Select Cervical Cancer

March 28th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use in combination with chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have a PD-L1 combined positive score of 1 or higher.

Concurrent Durvalumab/Chemoradiation Misses PFS End Point in Locally Advanced Cervical Cancer

March 24th 2022

Durvalumab given concurrently with chemoradiation was not found to significantly improve progression-free survival vs chemoradiation alone in patients with locally advanced cervical cancer, missing the primary end point of the phase 3 CALLA trial.

Endometrial Carcinoma: Clinical Case Scenario 3

March 24th 2022

Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.

Trastuzumab in Endometrial Carcinoma Therapy

March 24th 2022

Dr David O’Malley explains when to add and remove trastuzumab during endometrial carcinoma therapy.

INNOVATE-3 Trial Examining Tumor Treating Fields in Platinum-Resistant Ovarian Cancer Recommended to Continue

March 24th 2022

An independent data monitoring committee has recommended that the phase 3 INNOVATE-3 trial exploring the safety and efficacy of tumor treating fields in combination with paclitaxel in patients with platinum-resistant ovarian cancer proceed to the final analysis.

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

March 22nd 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Abemaciclib/Letrozole Combo Shows Promise in Recurrent ER+ Endometrial Cancer

March 22nd 2022

The combination of abemaciclib and letrozole produced encouraging responses with an acceptable toxicity profile in patients with estrogen receptor–positive, recurrent or metastatic endometrial cancer with endometrioid histology, according to data from a phase 2 trial.

The KEYNOTE-775 Trial: Efficacy of Combination Lenvatinib/Pembrolizumab in Endometrial Cancer

March 22nd 2022

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

First-line Treatment Options for Advanced Endometrial Cancer

March 22nd 2022

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

FDA Approves Pembrolizumab for Select MSI-H/dMMR Advanced Endometrial Cancer

March 21st 2022

The FDA has approved pembrolizumab for use as a single agent in the treatment of patients with advanced endometrial carcinoma that is microsatellite instability–high or mismatch repair deficient, and who experienced disease progression following previous systemic therapy in any setting and are not candidates for curative surgery or radiation.

Dr. Matulonis on the Results of the Phase 3 SORAYA Trial in Platinum-Resistant Ovarian Cancer

March 21st 2022

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.

Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma

March 21st 2022

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer

March 20th 2022

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Maintenance Selinexor Improves PFS Vs Placebo in Advanced or Recurrent Endometrial Cancer

March 20th 2022

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

March 20th 2022

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.